Cervical Cancer Treatment in Hyderabad
Reviewed May 2026 · Dr. Madhav Danthala
Cervical cancer is one of the most preventable cancers — through HPV vaccination and regular screening — yet remains a leading cause of cancer death in Indian women. Dr. Madhav Danthala provides treatment planning, chemoradiation, chemotherapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.
When to See a Doctor
Most causes of these symptoms are benign. Persistence — and any bleeding after menopause — warrants prompt evaluation.
Dr. Danthala's Approach
Cervical cancer is the cancer where prevention works best — and treatment results best when stage-led. Three principles shape every consultation.
-
Stage-led planning
Treatment intensity matches stage. Early-stage disease is often surgically curable. Locally advanced disease responds well to chemoradiation. Both pathways have well-defined protocols.
-
Fertility consideration
For young women with early-stage disease, fertility-sparing options (trachelectomy) are discussed early — before surgical or radiation decisions are committed.
-
Clear, structured communication
Every consult ends with a written summary of the plan, expected timeline, and the trade-offs each option carries.
Treatment Options
Cervical cancer treatment is mostly stage-led with well-defined protocols. For young women with early-stage disease, fertility-sparing options are part of the conversation early. Below are the major modalities.
Radical hysterectomy or fertility-sparing trachelectomy
For early-stage cervical cancer (IA, IB1, IIA), radical hysterectomy with pelvic lymph node dissection is the standard. Sentinel lymph node mapping is increasingly used to reduce morbidity. For young women with small tumours who wish to preserve fertility, radical trachelectomy (removing the cervix while preserving the uterus) is an option in carefully selected cases. Cone biopsy alone is curative for very early microscopic disease.
Concurrent cisplatin + external beam + brachytherapy
For locally advanced disease (IB3 to IVA), concurrent chemoradiation is the standard of care: weekly cisplatin combined with external-beam radiation followed by brachytherapy boost. The full course typically takes 6-8 weeks and is curative-intent. The KEYNOTE-A18 trial has now established a role for adjuvant pembrolizumab added to chemoradiation, further improving outcomes.
Cisplatin/paclitaxel, bevacizumab, pembrolizumab
For recurrent or metastatic disease, the standard is cisplatin or carboplatin combined with paclitaxel, often with bevacizumab (anti-VEGF). Pembrolizumab + chemotherapy is now first-line for PD-L1+ disease (KEYNOTE-826). Tisotumab vedotin (an antibody-drug conjugate) is approved for second-line treatment. Trials of HPV-targeted approaches and dual-checkpoint immunotherapy continue to expand the menu.
LEEP, cone biopsy for CIN — preventing progression
Cervical pre-cancer (CIN 2/3, AIS) detected by Pap or HPV screening is treated with loop electrosurgical excision (LEEP) or cold-knife conization — outpatient procedures that remove the abnormal area before invasive cancer can develop. This is one of oncology's clearest examples of prevention working: the screening + treatment of pre-cancer prevents the cancer.
Treatment is shaped by stage, fertility goals, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
Frequently Asked Questions
Should my child get the HPV vaccine?
Yes. Given between ages 9 and 14 (catch-up to 26), the HPV vaccine prevents the strains that cause nearly all cervical cancers. One of the most effective cancer-prevention tools available. Both girls and boys benefit — the same vaccine also prevents HPV-driven throat (oropharyngeal) cancers, which are rising in incidence in both sexes.
What's the difference between Pap smear and HPV test?
The Pap smear looks for abnormal cells. The HPV test looks for the virus that causes them. HPV testing is now the gold standard for primary screening — detects high-risk HPV early, before cell changes develop. In India, most centres still default to Pap.
At what age should screening start?
Cervical cancer screening typically begins at age 25 to 30 with HPV testing or at age 21 with Pap smear. Frequency depends on the test used — every 3 to 5 years for normal results. Continue through age 65 if consistently normal.
What are the warning signs?
Bleeding after intercourse, bleeding between periods, persistent unusual vaginal discharge, pelvic pain, or bleeding after menopause. Most causes are benign — but persistence warrants gynaecological evaluation, especially in unscreened women.
What does treatment involve?
Early-stage: surgery (radical hysterectomy or fertility-sparing trachelectomy). Locally advanced: chemoradiation. Recurrent or metastatic: chemotherapy plus immunotherapy (pembrolizumab) and anti-VEGF targeted therapy.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Cervical Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Cervical Cancer US National Cancer Institute clinical treatment summaries.
From our blog
- The Two-Oncologist Rule: When to Get a Second Opinion For young women weighing fertility-sparing trachelectomy versus radical hysterectomy, a second opinion is almost always worth the visit.
- Your Mother's Medical History Is Your Screening Map Family conversations about gynaecologic cancer history shape when screening should start — and which tests are appropriate.